Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
QNTM
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
finance.yahoo.comPOSITIVO
Why Thermo Fisher Scientific (TMO) Is Back In The Spotlight
Thermo Fisher Scientific (TMO) just appeared in the headlines after its clinical research business signed a Study Start-Up Agreement with Quantum BioPharma to run a Phase 2 multiple sclerosis trial for Lucid-MS. For context, Thermo Fisher…
Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
New agreement moves innovative Lucid-MS treatment from planning into execution. Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. Thermo Fis…
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Quantum BioPharma Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -…
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Quantum BioPharma Ltd. (NASDAQ:QNTM) on Tuesday said it is partnering with the clinical research division of Thermo Fisher Scientific Inc.(NYSE:TMO) to launch a Phase 2 clinical trial for its multiple sclerosis treatment, Lucid-MS. The com…
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Quantum BioPharma Ltd. NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Br…
D-Wave, Rigetti, Quantinuum land $100M each in CHIPS Act funding
D-Wave Quantum, Rigetti Computing, and Quantinuum each finalized definitive agreements with the U.S. Department of Commerce on Tuesday for $100 million apiece in CHIPS and Science Act funding, with the federal government taking a minority,…
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Quantum BioPharma THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Quan…
Quantum BioPharma Announces Closing of Debt Settlement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
Quantum BioPharma Announces Intention to Settle Debt
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 20, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
The Quest to Repair What Multiple Sclerosis Takes Away
AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people acr…
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are li…
Quantinuum QNT stock surges above IPO price on Nasdaq debut
Thursday's Nasdaq debut put Quantinuum shares at $68 when trading began, a 13% premium over the IPO price that translated into a market capitalization of approximately $17.6 billion. Pricing was set Wednesday night at $60 a share — topping…
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, is pleased to an…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, anno…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
TORONTO, March 23, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative asset…
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 10, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.…
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and…
Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors
LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma, Ltd., (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that bought securities between January 6, 2…
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and…
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and…
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and…
Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors
LOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that bought securities between January 6, 202…
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and…
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM). Such investors are advised to c…
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM). Such investors are advised to c…
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and…
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and…
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength
(RTTNews) - Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments. Kura Oncology, Inc. (KURA) led the group with…